Simnotrelvir/ritonavir (trade name Xiannuoxin) is a pharmaceutical drug used for the treatment of COVID-19. Simnotrelvir/ritonavir is a combination drug of simnotrelvir, an inhibitor of SARS-CoV-2 3CLpro, and ritonavir, a CYP3A inhibitor.

It was developed by Simcere Pharmaceutical and conditionally approved in China by the National Medical Products Administration (NMPA) in January 2023. Results for the phase Ib trial are available. In a phase II/III trial, it reduced the duration of symptoms by a median of 36 hours compared to placebo.

See also

External links

  • , also shows adverse effect data from phase II/III